Clinical Trial Update: Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety of CD19-targeted CAR-T cell therapy produced at Gustave Roussy for adults with severe and refractory systemic autoi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Inflammatory Myopathy
• Rheumatoid Arthritis
• Sjögren Syndrome
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• CD19-targeted CAR-T cell therapy

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 1 | Status: NOT_YET_RECRUITING